Source: Annual Congress 2009 - Airways remodelling
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Delimpoura, P. Bakakos, D. Simoes, E. Tseliou, V. Bessa, G. Hillas, G. Papadaki, K. Matzouranis, C. Roussos, S. Papiris, S. Loukides (Athens, Greece). Osteopontin in severe refractory asthma. Eur Respir J 2009; 34: Suppl. 53, 1331

Member's Comments

No comment yet.

Related content which might interest you: Eosinophilic refractory inflammation in OCS-dependent severe asthma Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Severe therapy-resistant asthma Source: International Congress 2016 – PG8 Paediatric asthma Year: 2016 Late-onset persistent eosinophilic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Effect of anti-IL5 treatment on symptoms of chronic rhinosinusitis, otitis and hearing loss in patients with severe eosinophilic asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Effect of ABPA treatment in severe asthma patients with acute and relapsed disease Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Management of severe and difficult-to-treat asthma Source: Annual Congress 2013 –Severe asthma: moving from phenotyping to endotyping Year: 2013 IL-33 in patients with severe uncontrolled allergic asthma Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Characterisation of patients with difficult-to-treat and treatment-resistant severe asthma Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers Year: 2012 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 Clinical features of steroid-resistant patients with severe steroid-dependent bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 133s Year: 2004 Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Severe asthma Source: International Congress 2014 – ERS/CTS China Day: advances in asthma and COPD Year: 2014